» Articles » PMID: 17592914

Short-term Naturalistic Treatment Outcomes in Cigarette Smokers with Substance Abuse And/or Mental Illness

Overview
Specialty Psychiatry
Date 2007 Jun 27
PMID 17592914
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The majority of cigarette smokers have a lifetime diagnosis of substance abuse and/or mental illness, and treatment outcomes for smokers with these comorbidities are generally reported to be worse than for smokers without comorbidities. We sought to examine the effect of specific substance abuse/mental illness diagnoses compared to one another on treatment outcomes.

Method: A retrospective chart review of naturalistic treatment for nicotine dependence was performed on male smokers (N = 231) who enrolled in the Greater Los Angeles Veterans Affairs Mental Health Clinic Smoking Cessation Program (Los Angeles, Calif.) over a 1.5-year period (January 2004 to June 2005). Subjects in this program, who were diagnosed with nicotine dependence on the basis of a DSM-IV-based interview and a Fagerström Test for Nicotine Dependence score of > or = 3, underwent comprehensive treatment for nicotine dependence (including, but not limited to, group psychotherapy, nicotine replacement therapy, and bupropion hydrochloride). Quitting smoking was defined as a report of at least 1 week of abstinence and an exhaled carbon monoxide less than or equal to 8 parts per million at the final clinic visit.

Results: Of the total group, 36.4% (84/231) quit smoking at the end of treatment. Quit rates were affected by the presence of specific diagnoses, with smokers with a history of alcohol abuse/dependence or schizophrenia/schizoaffective disorder having poorer response rates than smokers without such diagnoses. Other substance abuse and mental illness diagnoses did not affect quit rates.

Conclusion: Lower quit rates among patients with alcohol abuse/dependence or schizophrenia/schizoaffective disorder may be due to the severity of these conditions and suggest that specialized treatment is needed for these populations of smokers. Smokers with most comorbid diagnoses are successfully treated with standard treatment methods.

Citing Articles

Implementation of Community Health Worker Support for Tobacco Cessation: A Mixed-Methods Study.

Foo C, Potter K, Nielsen L, Rohila A, Maravic M, Schnitzer K medRxiv. 2024; .

PMID: 38343842 PMC: 10854356. DOI: 10.1101/2024.01.26.24301835.


Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Brody A, Zorick T, Hubert R, Hellemann G, Balali S, Kawasaki S Nicotine Tob Res. 2016; 19(1):68-76.

PMID: 27613888 PMC: 5157714. DOI: 10.1093/ntr/ntw190.


Abstinence and Use of Community-Based Cessation Treatment After a Motivational Intervention Among smokers with Severe Mental Illness.

Ferron J, Devitt T, McHugo G, Jonikas J, Cook J, Brunette M Community Ment Health J. 2016; 52(4):446-56.

PMID: 26932324 DOI: 10.1007/s10597-016-9998-1.


Frequency of Psychiatric Disorders in Children of Opioid or Methamphetamine-Dependent Patients.

Parvaresh N, Mazhari S, Nazari-Noghabi M Addict Health. 2016; 7(3-4):140-8.

PMID: 26885350 PMC: 4741234.


The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods.

Lan C, Fiellin D, Barry D, Bryant K, Gordon A, Edelman E Am J Addict. 2015; 25(1):7-24.

PMID: 26693830 PMC: 5123305. DOI: 10.1111/ajad.12319.


References
1.
Hurt R, Patten C, Offord K, Croghan I, Decker P, Morris R . Treating nondepressed smokers with alcohol dependence in sustained full remission: nicotine patch therapy tailored to baseline serum cotinine. J Stud Alcohol. 2005; 66(4):506-16. DOI: 10.15288/jsa.2005.66.506. View

2.
De Leon J, Susce M, Diaz F, Rendon D, Velasquez D . Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry. 2006; 66(11):1447-55. DOI: 10.4088/jcp.v66n1112. View

3.
George T, Vessicchio J, Termine A, Bregartner T, Feingold A, Rounsaville B . A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002; 52(1):53-61. DOI: 10.1016/s0006-3223(02)01339-2. View

4.
Richter K, Ahluwalia H, Mosier M, Nazir N, Ahluwalia J . A population-based study of cigarette smoking among illicit drug users in the United States. Addiction. 2002; 97(7):861-9. DOI: 10.1046/j.1360-0443.2002.00162.x. View

5.
Hughes J, Callas P . Past alcohol problems do not predict worse smoking cessation outcomes. Drug Alcohol Depend. 2003; 71(3):269-73. DOI: 10.1016/s0376-8716(03)00139-x. View